Amanda F Saltzman1, Nicholas G Cost2. 1. Department of Surgery, Division of Urology, University of Colorado School of Medicine & Children's Hospital Colorado, 13123 E 16th Ave., Box 463, Aurora, CO, 80045, USA. 2. Department of Surgery, Division of Urology, University of Colorado School of Medicine & Children's Hospital Colorado, 13123 E 16th Ave., Box 463, Aurora, CO, 80045, USA. nicholas.cost@childrenscolorado.org.
Abstract
PURPOSE OF REVIEW: Rhabdomyosarcoma (RMS) is the most common sarcoma diagnosed in the first 20 years of life; bladder/prostate (BP) RMS accounts for 5% of all cases. Through efforts from multiple cooperative study groups, survival has improved significantly. This article aims to review the complex RMS classification system and treatment of BP RMS, with a focus on developing aspects of treatment. RECENT FINDINGS: Recent advancements in technology are responsible for most of the progress in RMS treatment. PET-CT scanning has been shown to be superior to conventional metastatic workup. The use of proton beam therapy and brachytherapy to reduce the side effects of radiation is also showing promise. All cooperative oncology groups agree on surgical biopsy for diagnosis and staging of BP RMS. Patients are then grouped and risk classified before receiving chemotherapy. Regardless of local control strategy, oncologic outcomes appear to be similar for BP RMS. Alternative treatment strategies, which remain unproven, include brachytherapy and proton therapy.
PURPOSE OF REVIEW: Rhabdomyosarcoma (RMS) is the most common sarcoma diagnosed in the first 20 years of life; bladder/prostate (BP) RMS accounts for 5% of all cases. Through efforts from multiple cooperative study groups, survival has improved significantly. This article aims to review the complex RMS classification system and treatment of BP RMS, with a focus on developing aspects of treatment. RECENT FINDINGS: Recent advancements in technology are responsible for most of the progress in RMS treatment. PET-CT scanning has been shown to be superior to conventional metastatic workup. The use of proton beam therapy and brachytherapy to reduce the side effects of radiation is also showing promise. All cooperative oncology groups agree on surgical biopsy for diagnosis and staging of BP RMS. Patients are then grouped and risk classified before receiving chemotherapy. Regardless of local control strategy, oncologic outcomes appear to be similar for BP RMS. Alternative treatment strategies, which remain unproven, include brachytherapy and proton therapy.
Authors: Matthew M Ladra; Jackie D Szymonifka; Anita Mahajan; Alison M Friedmann; Beow Yong Yeap; Claire P Goebel; Shannon M MacDonald; David R Grosshans; Carlos Rodriguez-Galindo; Karen J Marcus; Nancy J Tarbell; Torunn I Yock Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Sheri L Spunt; Teresa A Sweeney; Melissa M Hudson; Catherine A Billups; Matthew J Krasin; Allison L Hester Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: R Heyn; W A Newton; R B Raney; A Hamoudi; C Bagwell; T Vietti; M Wharam; E Gehan; H M Maurer Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: Ana Domínguez; Javier Lorca; David López-Curtis; Vital Hevia; Enrique Sanz; Francisco Javier Burgos Revilla Journal: Urol Case Rep Date: 2022-04-20